Xilio Therapeutics (NASDAQ:XLO) Announces Earnings Results, Beats Expectations By $0.02 EPS

Xilio Therapeutics (NASDAQ:XLO) announced its quarterly earnings results on Tuesday. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.02, Zacks reports. The company had revenue of $1.72 million during the quarter, compared to analysts’ expectations of $2.26 million.

Xilio Therapeutics Stock Performance

NASDAQ XLO opened at $0.83 on Thursday. The firm has a market cap of $36.27 million, a PE ratio of -0.48 and a beta of -0.38. Xilio Therapeutics has a one year low of $0.58 and a one year high of $1.93. The firm’s fifty day moving average is $0.94 and its two-hundred day moving average is $0.94.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.